Edwards Lifesciences to acquire CASMED for $100M

Edwards Lifesciences has entered into a definitive merger agreement to acquire CAS Medical Systems (CASMED) for $2.45 per share, or an equity value of approximately $100 million. The acquisition is expected to close in the second quarter of 2019.

“We believe the incorporation of CASMED's FORE-SIGHT technology into Edwards' leading hemodynamic monitoring platform will strengthen Edwards' leadership in smart monitoring technologies.”edwards.com

• 1 source
• edwards.comEdwards Lifesciences Enters Into Agreement To Acquire CASMED | Edwards LifesciencesFeb 12, 2019

Summarized from public sources; check the original articles before acting on it.